Show simple item record

dc.contributor.authorZamanlu, M
dc.contributor.authorFarhoudi, M
dc.contributor.authorEskandani, M
dc.contributor.authorMahmoudi, J
dc.contributor.authorBarar, J
dc.contributor.authorRafi, M
dc.contributor.authorOmidi, Y
dc.date.accessioned2018-08-26T07:13:17Z
dc.date.available2018-08-26T07:13:17Z
dc.date.issued2018
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/44926
dc.description.abstractTissue plasminogen activator (tPA) is the only FDA approved medical treatment for the ischaemic stroke. However, it associates with some inevitable limitations, including: short therapeutic window, extremely short half-life and low penetration in large clots. Systemic administration may lead to complications such as haemorrhagic conversion in the brain and relapse in the form of re-occlusion. Furthermore, ultrasound has been utilised in combination with contrast agents, echogenic liposome, microspheres or nanoparticles (NPs) carrying tPA for improving thrombolysis - an approach that has resulted in slight improvement of tPA delivery and facilitated thrombolysis. Most of these delivery systems are able to extend the circulating half-life and clot penetration of tPA. Various technologies employed for ameliorated thrombolytic therapy are in different phases, some are in final steps for clinical applications while some others are under investigations for their safety and efficacy in human cases. Here, recent progresses on the thrombolytic therapy using novel nano- and micro-systems incorporating tPA are articulated. Of these, liposomes and microspheres, polymeric NPs and magnetic nanoparticles (MNPs) are discussed. Key technologies implemented for efficient delivery of tPA and advanced thrombolytic therapy and their advantages/disadvantages are further expressed.
dc.language.isoEnglish
dc.relation.ispartofJOURNAL OF DRUG TARGETING
dc.subjectThrombolytic therapy
dc.subjectfibrinolysis
dc.subjecttPA delivery
dc.subjecttargeted delivery
dc.subjectthrombolysis
dc.subjectischaemic stroke
dc.titleRecent advances in targeted delivery of tissue plasminogen activator for enhanced thrombolysis in ischaemic stroke
dc.typeReview
dc.citation.volume26
dc.citation.issue2
dc.citation.spage95
dc.citation.epage109
dc.citation.indexWeb of science
dc.identifier.DOIhttps://doi.org/10.1080/1061186X.2017.1365874


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record